Appendix 4C and Quarterly Activities Report - December 2025
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
Invion Limited ABN 76 094 730 417
Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000
P: +61 3 9692 7222 W: www.inviongroup.com
ACTIVITY REPORT AND CASH FLOW REPORT
FOR THE QUARTER ENDED 31 DECEMBER 2025
Highlights:
Non-Dilutive Korean Government Grant: Hanlim Pharm, supported by the South Korean
Government’s KDDF, commits up to ~$2M to preclinical studies and regulatory
preparation for clinical trial using intravenously administered INV043 for the treatment
of oesophageal cancer.
Exclusive Global Licensing: Invion secures perpetual exclusive global licence to the
Photosoft™ platform technology across several human and animal disease indications
worldwide.
Additional Funding & Collaboration Partnership: Taiwan-listed Protect Animal Health to
fund and undertake evaluation studies using Photosoft for the treatment of cancer in
companion animals, with Invion to retain all rights to its technology.
Strengthening the Balance Sheet: Secured $400K R&D advance facility and successfully
raised $1.3M via convertible note issue with one of Invion’s largest shareholders and its
Exec Chair, Prof Thian Chew, acting as cornerstone investors in the raise.
MELBOURNE (AUSTRALIA) 30 January 2026: Invion Limited (ASX: IVX) (“Invion” or the
“Company”) wishes to provide the following update and Appendix 4C for the quarter ended
31 December 2025 (2QFY26).
Summary of cash position and expenditure during the quarter
The Company held cash reserves at the end of the quarter of $138K (4QFY25: $537K), which
excludes the $1.3M (before costs) in proceeds from the issue of convertible notes announced
today and a $400K R&D advance facility (more details below)
Invion’s key cash outflows under Operating Activities in the quarter were research and
development costs of $314K (1QFY26: $444K) and administration and corporate costs of $188K
(1QFY26: $321K).
As detailed in Item 6.1 of the accompanying Appendix 4C, the Company discloses that the
aggregate payments to related parties and their associates during the quarter totalled $39K.
The related party payments relate to payment to Vistra Australia for Directors’ fees and CFO
and company secretarial fees during the quarter.
Key developments
Invion is developing the Photosoft™ platform technology with its key focus on its clinical cancer
programs. The Company achieved several key milestones in the quarter to advance Photosoft
in multiple cancer indications across both human and animal health, strengthening its long-
term commercial outlook.
Non-Dilutive South Korean Government Grant
In late December 2025, Invion announced a significant non-dilutive funding arrangement
through a collaboration with Hanlim Pharm Co., Ltd, supported by a grant from the South
Korean government’s Korea Drug Development Fund (KDDF).
The arrangement provides up to $2 million to fund preclinical studies and regulatory
preparation for a planned first-in-human clinical trial in Australia of intravenously administered
ASX ANNOUNCEMENT
Invion Limited ABN 76 094 730 417
Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000
P: +61 3 9692 7222 W: www.inviongroup.com
INV043 for the treatment of oesophageal cancer. This funding minimises shareholder dilution
and reflects strong international validation of the Photosoft technology platform.
There remains an urgent medical need for effective treatments for oesophageal cancer. The
disease often develops without obvious symptoms and is frequently diagnosed only at an
advanced stage – contributing to its poor five-year survival rate of around 21%1. Existing
treatment options, including surgery and chemotherapy, can be highly invasive and are often
accompanied by severe side effects. Meanwhile, newer approaches, such as
immunotherapies, have shown promise but tend to benefit only a limited proportion of
patients.
The global market for oesophageal cancer therapies is valued at approximately US$15.3 billion
in 2025 and is projected to expand at a compound annual growth rate of 8.2%, reaching circa
US$36.6 billion by 20352.
Expanded Exclusive Global License
The KDDF funding comes on the back of another significant milestone announced earlier the
same month, where Invion secured an expanded perpetual and exclusive global licence to
the Photosoft technology.
This expanded licence materially enhanced Invion’s strategic position by removing a key
overhang and granting broader rights to develop, manufacture and commercialise the
technology across several human and animal disease indications worldwide3. The expanded
licence underpins Invion’s long-term platform strategy and potential future partnering and
commercialisation opportunities.
Other Achievements
Invion signed an agreement with Taiwan-listed company, Protect Animal Health Inc. (7850.TT)
(Protect), to fund and undertake evaluation studies using Photosoft for the treatment of
cancer in companion animals.
Protect, a company with a mission to bring advanced therapeutics to the growing companion
animal health market, will fund and conduct in vitro, in vivo and companion animal studies
using select Photosoft compounds provided by Invion, which will retain all rights to the
Photosoft technology and any new intellectual property from the studies.
There is an urgent need for new cancer therapies to treat the growing incidence of cancer in
companion animals as pet ownership grows globally. Around half of dogs over the age of 10
will develop cancer4. Current treatments tend to be lengthy and use older cancer
therapeutics, which can have sub-optimal outcomes.
Separately, Invion fully repaid outstanding amounts with Lind Global Fund II LP (Lind) in the
quarter. The Company has no further obligations to Lind following the repayment.
Post End-of-Quarter Events
Invion successfully raised $1.3 million via a convertible note offering to strengthen its capital
position. Invion’s largest shareholder and Executive Chair, Prof Thian Chew, and a top five
largest shareholder, Ms Xiaoyi Wu, were the cornerstone investors in the raise.
1
https://www.medicalnewstoday.com/articles/esophageal-cancer-treatment-success-rate#faq
2
https://www.marketresearchfuture.com/reports/esophageal-cancer-market-3280
3 https://announcements.asx.com.au/asxpdf/20251203/pdf/06sw1w97b9vhks.pdf
4
https://www.avma.org/resources/pet-owners/petcare/cancer-pets
ASX ANNOUNCEMENT
Invion Limited ABN 76 094 730 417
Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000
P: +61 3 9692 7222 W: www.inviongroup.com
The convertible notes, which have a three-year term, will help to secure Invion’s longer-term
goals and the convertible pricing supports confidence in the upside potential of the Company.
Additionally, Invion secured a non-dilutive $400K R&D advance facility that uses the
Company’s future R&D tax rebate as collateral.
Commenting on the latest quarter, Prof Chew, said:
“The past few months marked a pivotal period for Invion, with multiple strategic
milestones significantly strengthening the Company’s clinical, commercial and
financial foundations. The strong support for our latest capital raise and the non-
dilutive funding from Hanlim and KDDF is an important validation of the Photosoft
technology.
“Additionally, the expansion of our perpetual and exclusive global licence to
Photosoft removed a key strategic overhang and materially enhanced our long-
term value proposition. Together, these developments position Invion with greater
control, flexibility and optionality as we progress our human and animal health
programs.”
Investing & Financing activities
Invion recorded a $128K net cash inflow from Financing Activities from the proceeds of the
previous convertible note offering, less repayments to Lind, and a $25K net cash outflow from
Investing Activities in the quarter relating to intellectual property.
This announcement was approved for release by the Board of Directors.
____________________________________________
Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate
in discussions: https://investors.inviongroup.com/
Investor and Media enquiries:
Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com
Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com
About Invion
Invion is a life-science company that is leading the global research and development of the
Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious
diseases. Invion holds the global exclusive license to the Photosoft technology for multiple
cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more
at www.Inviongroup.com.
ASX ANNOUNCEMENT
Invion Limited ABN 76 094 730 417
Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000
P: +61 3 9692 7222 W: www.inviongroup.com
About Next Generation Photodynamic Therapy (NGPDT)
Invion is developing PhotosoftTM technology as a novel Next Generation Photodynamic
Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells
and promote an anti-cancer immune response. Less invasive than surgery and with minimal
side effects, NGPDT offers an alternative treatment option aimed at achieving complete
tumour regression and long-lasting remission. NGPDT has also demonstrated broad-spectrum
activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has
the potential to address the global challenge of antibiotic-resistant “superbugs”.
Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 1
+ See chapter 19 of the ASX Listing Rules for defined terms.
General
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
INVION LTD
ABN Quarter ended (“current quarter”)
76 094 730 417 31 December 2025
Consolidated statement of cash flows Current quarter
$A’000
Year to date
(6 months)
$A’000
1. Cash flows from operating activities
- -
1.1 Receipts from customers
1.2 Payments for
(314) (758)
(a) research and development
(b) product manufacturing and operating
costs
- -
(c) advertising and marketing - -
(d) leased assets - -
(e) staff costs - -
(f) administration and corporate costs (188) (509)
1.3 Dividends received (see note 3) - -
1.4 Interest received - -
1.5 Interest and other costs of finance paid - -
1.6 Income taxes paid - -
1.7 Government grants and tax incentives - -
1.8 Other (provide details if material) - -
1.9 Net cash from / (used in) operating
activities
(502) (1,267)
2. Cash flows from investing activities
- -
2.1 Payments to acquire or for:
(a) entities
(b) businesses - -
(c) property, plant, and equipment - -
(d) investments - -
(e) intellectual property (25) (25)
(f) other non-current assets - -
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 2
+ See chapter 19 of the ASX Listing Rules for defined terms.
General
Consolidated statement of cash flows Current quarter
$A’000
Year to date
(6 months)
$A’000
2.2 Proceeds from disposal of:
- -
(a) entities
(b) businesses - -
(c) property, plant and equipment - -
(d) investments - -
(e) intellectual property - -
(f) other non-current assets - -
2.3 Cash flows from loans to other entities - -
2.4 Dividends received (see note 3) - -
2.5 Other (provide details if material) - -
2.6 Net cash from / (used in) investing
activities
(25) (25)
3. Cash flows from financing activities
- 981
3.1 Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2 Proceeds from issue of convertible debt
securities
782 782
3.3 Proceeds from exercise of options - -
3.4 Transaction costs related to issues of
equity securities or convertible debt
securities
- (37)
3.5 Proceeds from borrowings - -
3.6 Repayment of borrowings - -
3.7 Transaction costs related to loans and
borrowings
- -
3.8 Dividends paid - -
3.9 Other – (Payment to Lind Partners) (654) (1,146)
3.10 Net cash from / (used in) financing
activities
128 580
4. Net increase / (decrease) in cash and
cash equivalents for the period
537 850
4.1 Cash and cash equivalents at beginning of
period
4.2 Net cash from / (used in) operating
activities (item 1.9 above)
(502) (1,267)
4.3 Net cash from / (used in) investing activities
(item 2.6 above)
(25) (25)
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 3
+ See chapter 19 of the ASX Listing Rules for defined terms.
General
Consolidated statement of cash flows Current quarter
$A’000
Year to date
(6 months)
$A’000
4.4 Net cash from / (used in) financing activities
(item 3.10 above)
128 580
4.5 Effect of movement in exchange rates on
cash held
- -
4.6 Cash and cash equivalents at end of
period
138 138
5. Reconciliation of cash and cash
equivalents
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
Current quarter
$A’000
Previous quarter
$A’000
5.1 Bank balances 138 537
5.2 Call deposits - -
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5 Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
138 537
6. Payments to related parties of the entity and their
associates
Current quarter
$A'000
6.1 Aggregate amount of payments to related parties and their
associates included in item 1
39
6.2 Aggregate amount of payments to related parties and their
associates included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 4
+ See chapter 19 of the ASX Listing Rules for defined terms.
General
7. Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1 Loan facilities - -
7.2 Credit standby arrangements - -
7.3 Other (please specify) - -
7.4 Total financing facilities - -
7.5 Unused financing facilities available at quarter end -
7.6 Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
NA
8. Estimated cash available for future operating activities $A’000
8.1 Net cash from / (used in) operating activities (item 1.9) (502)
8.2 Cash and cash equivalents at quarter end (item 4.6) 138
8.3 Unused finance facilities available at quarter end (item 7.5) -
8.4 Total available funding (item 8.2 + item 8.3) 138
8.5 Estimated quarters of funding available (item 8.4 divided by
item 8.1)
0.27
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
No. Please refer to 8.6.2 for detailed explanation.
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
As announced today, Invion has received commitments for $1.3 million funding via
Convertible Notes arrangement, with $578k to be received in the coming week and
the balance, subject to shareholder approval is expected to be received prior to the
end of Q326. The Company is preparing to lodge its R&D tax incentive claim for
financial year ended 30 June 2025. In addition, subsequent to the quarter end, the
company has secured access to a R&D tax incentive financing facility for
approximately $400k. Further, Invion has the flexibility to manage its operating costs
by slowing or accelerating its clinical program. It also made a number of one-off
payments during the quarter that are not expected to be repeated in the coming
quarters.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 5
+ See chapter 19 of the ASX Listing Rules for defined terms.
General
8.6.3 Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Yes, the Company expects to be able to continue its operations and meet its
business objectives based on the answer to question 8.6.2 above.
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1 This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
Date: 30 January 2026
Authorised by: By the Board...................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
Share your feedback
Discover